Cardiac Arrhythmia Treatment: New Target Found
- A collaborative study by the university of Arizona College of Medicine -- Phoenix and University of California Davis Health has pinpointed a novel target for therapeutic intervention in...
- AFib, also known as AF, is implicated in approximately one in seven strokes, according to the Centers for Disease Control and Prevention. It substantially elevates the risk of...
- For some time, proteins involved in heart function have been a focus of AFib research.
Researchers have identified a new target for atrial fibrillation therapy, offering a critically important step forward in treating this widespread heart rhythm disorder. This breakthrough focuses on the mechanisms of the SK2 channel,aiming to provide new avenues for cardiac arrhythmia treatment. The study highlights the role of PIP2 in regulating these channels, offering crucial insights into potential therapeutic interventions for AFib patients. This research, featured in the Proceedings of the National Academy of Sciences, underscores the critical need for innovative approaches to treat atrial fibrillation. Learn how this discovery could change the landscape of heart health. For more facts, visit News Directory 3. Discover what’s next.
New Target Identified for Atrial Fibrillation Therapy
Updated June 23, 2025
A collaborative study by the university of Arizona College of Medicine — Phoenix and University of California Davis Health has pinpointed a novel target for therapeutic intervention in atrial fibrillation (AFib), the most prevalent form of irregular heartbeat.
AFib, also known as AF, is implicated in approximately one in seven strokes, according to the Centers for Disease Control and Prevention. It substantially elevates the risk of illness and death. The american Heart Association projects that over 12 million individuals will be affected by AFib by 2030, highlighting the inadequacy of current treatments, researchers noted.
For some time, proteins involved in heart function have been a focus of AFib research. Earlier studies suggested that inhibiting specific small-conductance calcium-activated potassium channels (SK channels) to treat AFib coudl either alleviate or exacerbate arrhythmias, depending on the circumstances.
“our research employed advanced experimental and computational methods to understand how the human SK2 channel is regulated,” said Dr. Nipavan Chiamvimonvat, chair of the Department of Basic Medical Sciences at the U of A College of Medicine — Phoenix. “Given that SK channel inhibitors are currently undergoing clinical trials for AFib, this insight into their regulatory mechanisms is crucial.”
The study, titled “Atomistic Mechanisms of the Regulation of Small Conductance Ca2+-Activated K+ channel (SK2) by PIP2,” was featured in Proceedings of the National Academy of Sciences.
The research team investigated the role of phosphatidylinositol 4,5-bisphosphate (PIP2), a lipid, in SK2 channel regulation. PIP2 is a key component of plant and animal cell membranes and serves as a messenger in various bodily signaling pathways.
“Because PIP2 is vital to multiple ion channels, its role in regulating cardiac ion channels presents a new mechanism for lipid regulation of cardiac excitability and function,” said Dr. Ryan Woltz,computational biologist and assistant research professor at the College of Medicine — Phoenix.
SK channels are the only known potassium channels that are upregulated in heart failure, and their regulation is critical in cardiac excitability and the development of heart rhythm disturbances.
“As PIP2 is known to be dysregulated in heart failure, our study provides critical translational insights into possible mechanisms of cardiac arrhythmias in heart failure,” said Dr. Yang Zheng, a postdoctoral research fellow at the College of Medicine — Phoenix.
The team used comparative modeling to create human SK2 channel models in closed, intermediate, and open states. They then used molecular dynamics simulations to explore how PIP2 modulates SK2 channels.
“Our study’s structural insights will be useful in designing new SK2 channel inhibitors to treat cardiac arrhythmias,” said Dr. Vladimir Yarov-Yarovoy, a professor at UC Davis Health.
Dr. Igor Vorobyov, an associate professor at UC Davis Health, said his team is using similar computational methods to study other SK channel subtypes.
“I am thrilled to participate in this collaborative multi-university and multidisciplinary research study and looking forward to a continued collaboration,” Vorobyov said. “We are currently working on applying a similar pioneering experimental/computational approach to modulation of SK channels by drug molecules, which may enhance or inhibit function of these ion channels and can be used as prospective treatment options for AFib and other cardiovascular diseases.”
What’s next
The researchers plan to continue exploring the modulation of SK channels by drug molecules, seeking to identify potential treatments for AFib and other cardiovascular diseases.